IDO1 and breast carcinoma: Differentiation of Tregs inhibits the activation of effector T cells, ultimately leading to local immunosuppression in the tumor microenvironment.[36] Therefore, inhibition of IDO presents a promising immunotherapy strategy for breast cancer by alleviating immunosuppression within the tumor microenvironment.